Author

Ruth Lira

Observed names: Ruth R Lira, Ruth R. Lira

Institutions: Stanford Cancer Institute, Stanford University

Observed institutions: Stanford Medicine, Stanford Cancer Institute, Stanford University

OpenAlex ID: A5000502532

Targeting CD137 enhances the efficacy of cetuximab

2014 · Holbrook E. Kohrt, A. Dimitrios Colevas, et al. · Journal of Clinical Investigation · 160

Discordance in routine second opinion pathology review of head and neck oncology specimens: A single-center five year retrospective review

2015 · Gefei Alex Zhu, Ruth Lira, et al. · Oral Oncology · 13

Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck

2018 · Vanessa Trieu, Harlan Pinto, et al. · The Oncologist · 9

Hearing evaluation of patients with head and neck cancer: Comparison of Common Terminology Criteria for Adverse Events, Brock and Chang adverse event criteria in patients receiving cisplatin

2014 · A. Dimitrios Colevas, Ruth R. Lira, et al. · Head & Neck · 9

Targeting CD137 enhances the efficacy of cetuximab

2019 · Holbrook E. Kohrt, A. Dimitrios Colevas, et al. · Journal of Clinical Investigation · 6

Targeting CD137 to enhance the antitumor efficacy of cetuximab by stimulation of innate and adaptive immunity.

2013 · Holbrook Edwin Kohrt, Roch Houot, et al. · Journal of Clinical Oncology · 4

In search for optimal induction chemotherapy for advanced nasopharyngeal cancer: Standard dosing of Docetaxel, Platinum, and 5-Fluorouracil (TPF) followed by chemoradiation

2023 · Michelle Jun, Harlan Pinto, et al. · PLoS ONE · 3

Review of pathologic diagnosis in head and neck cancer patients: Why do it?

2014 · Gefei Alex Zhu, Ruth R Lira, et al. · Journal of Clinical Oncology

Hearing evaluation of head and neck cancer patients (HNCP): Comparison of adverse event (AE) criteria.

2012 · A. Dimitrios Colevas, Ruth R Lira, et al. · Journal of Clinical Oncology

Works count: 9

Citation count: 204

H-index: 5

I10-index: 2